| 杜忠礼,许成山,边志民.三磷酸腺苷结合盒转运体C2基因遗传变异与TA方案新辅助化疗乳腺癌患者骨髓抑制的关联研究[J].中国肿瘤,2020,29(4):309-315. |
| 三磷酸腺苷结合盒转运体C2基因遗传变异与TA方案新辅助化疗乳腺癌患者骨髓抑制的关联研究 |
| Association of ABCC2 Gene Polymorphism with Myelosuppression in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy of TA Regimen |
| 中文关键词 修订日期：2020-02-18 |
| DOI：10.11735/j.issn.1004-0242.2020.04.A012 |
|
 |
| 中文关键词: 乳腺肿瘤 三磷酸腺苷结合盒转运体C2基因 多态性，单核苷酸 新辅助化疗 骨髓抑制 |
| 英文关键词:breast neoplasms ABCC2 gene polymorphism,single nucleotide neoadjuvant chemotherapy myelosuppression |
| 基金项目:北京医院院级科研课题（BJ-2015-103） |
|
| 摘要点击次数: 1782 |
| 全文下载次数: 281 |
| 中文摘要: |
| 摘 要：［目的］ 探讨三磷酸腺苷结合盒转运体C2（ATP binding cassette subfamily C member 2，ABCC2）基因单核苷酸多态性（single nucleotide polymorphism，SNP）与TA方案（紫衫类药物+蒽环类药物）新辅助化疗乳腺癌患者骨髓抑制的相关性。［方法］ 556例采用TA方案新辅助化疗的女性乳腺癌患者，化疗前抽取2ml静脉血，筛选标签SNP，采用Sequenom MassARRAY基因分型平台进行标签SNP分型，并分析标签SNP与乳腺癌患者骨髓抑制的关系。采用多因素Logistic回归分析计算风险比及其95%可信区间。［结果］ 筛选出3个标签SNP rs717620、rs3740066、rs2273697。与携带rs717620CC基因型相比，携带rs717620 CT基因型患者骨髓抑制程度更重，OR及其95%CI为 1.72（1.18~2.52）。与携带rs3740066 CC基因型相比，携带rs3740066 CT基因型患者骨髓抑制程度更重，OR及其95%CI为 1.47（1.02~2.12）。累积分析显示，随着风险基因型个数的增加，乳腺癌新辅助化疗患者的骨髓抑制风险增加，OR及其95%CI为 1.27（1.05~1.53）；与0个风险基因型相比，携带2个风险基因型患者骨髓抑制程度更重，OR及其95%CI为 1.30（1.07~1.57）。［结论］ ABCC2基因rs717620和rs3740066与TA方案新辅助化疗乳腺癌患者的骨髓抑制相关，可作为预测乳腺癌新辅助化疗患者骨髓抑制的生物标志物。 |
| 英文摘要: |
| Abstract：［Purpose］ To assess the association of single nucleotide polymorphisms(SNPs) in ABCC2(ATP binding cassette subfamily C member 2) gene with myelosuppression of breast cancer(BC) patients undergoing neoadjuvant chemotherapy of TA(taxane and antharcycline) regimen. ［Methods］ Total 556 female BC patients were recruited and treated with neoadjuvant chemotherapy of TA regimen. Blood samples were collected from patients before chemotherapy. Tagging SNPs(tag-SNPs) were selected，and the association of tag-SNPs with myelosuppression was analyzed by Sequenom Mass ARRAY system platform. The odds ratios(ORs) and 95% confidence intervals(CIs) for myelosuppression were calculated by multivariate logistic regression model. ［Results］ Three tag-SNPs(rs717620，rs3740066，rs2273697) were selected for study. Compared with individuals carrying rs717620 CC genotype，the risk of myelosuppression was significantly increased in individuals carrying rs717620 CT genotype(OR=1.72，95%CI：1.18～2.52，P<0.005). Compared with individuals carrying the rs3740066 CC genotype，the risk of myelosuppression was significantly increased in individuals carrying rs3740066 CT genotype had worse myelosuppression(OR=1.47，95%CI：1.02～2.12，P<0.038). Accumulation analysis showed that with the increase of the number of risk genotypes，the risk of myelosuppression increased(OR=1.27，95%CI：1.05~1.53，P<0.013). Compared with individuals carrying no risk genotype，individuals carrying two risk genotypes had worse myelosuppression(OR=1.30，95%CI：1.07~1.57，P<0.008). ［Conclusion］ The variations of rs717620 and rs3740066 in ABCC2 gene are significantly associated with myelosuppression，which might serve as biomarkers for predicting myelosuppression in BC patients treated with neoadjuvant chemotherapy of TA regimen. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |